Dendritic cell vaccination in an allogeneic stem cell recipient receiving a transplant from a human cytomegalovirus (HCMV)-seronegative donor: Induction of a HCMV-specific Thelper cell response

Cytotherapy

Volumn 12, Issue 7, 2010, Pages 945-950

  Feuchtinger, Tobias ^a   Opherk, Kathrin ^a   Bicanic, Oliver ^a   Schumm, Michael ^a   Grigoleit, Götz Ulrich ^b   Hamprecht, Klaus ^c   Jahn, Gerhard ^c   Handgretinger, Rupert ^a   Lang, Peter ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

allogeneic stem cell transplantation; cytomegalovirus infection; dendritic cell vaccination

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; FEMALE; GRAFT REJECTION; HELPER CELL; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; VIREMIA; VIRUS REACTIVATION;

EID: 77953514450     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653241003587645     Document Type: Article

References (20)

1. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004;103:2003-8.
2. Ljungman P, Brand R, Einsele H, et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood. 2003;102:4255-60.
3. Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9:543-58.
4. Ljungman P, Reusser P, de la Camara R, et al. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant. 2004;33:1075-81.
5. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003;362:1375-7.
6. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916-3922.
7. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med. 2005; 201:1031-6.
8. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202:379-86.
9. Schottker B, Feuchtinger T, Schumm M, et al. Five donors-one recipient: modeling a mosaic of granulocytes, natural killer and T cells from cord-blood and third-party donors. Nat Clin Pract Oncol. 2008;5:291-5.
10. Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with pep-tide-pulsed dendritic cells. Blood. 2000;96:3102-8.
11. Grigoleit GU, Kapp M, Hebart H, et al. Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor. J Infect Dis. 2007; 196: 699-704.
12. + cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant. 1994;14(Suppl 4):S78-84.
13. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-44.
14. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus inter-leukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-18.
15. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134: 64-76.
16. Schumm M, Feuchtinger T, Pfeiffer M, et al. Flow cytometry with anti HLA-antibodies: a simple but highly sensitive method for monitoring chimerism and minimal residual disease after HLA-mismatched stem cell transplantation. Bone Marrow Transplant. 2007;39:767-73.
17. Gohring K, Feuchtinger T, Mikeler E, et al. Dynamics of the emergence of a human cytomegalovirus UL97 mutant strain conferring ganciclovir resistance in a pediatric stem-cell transplant recipient. J Mol Diagn. 2009;11:364-8.
18. Eckle T, Prix L, Jahn G, et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood. 2000;96:3286-9.
19. Serangeli C, Bicanic O, Scheible MH, et al. Ex vivo detection of adenovirus specific CD4(+) T-cell responses to HLA-DR-epitopes of the Hexon protein show a contracted specificity of T(helper) cells following stem cell transplantation. Virology. 2010;397(2):277-84. Epub 2009 Dec 3. 20.
20. + T cells after acute infection. Nat Immunol. 2004;5:927-33.